Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Rating of “Hold” by Brokerages

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) has been given an average rating of “Hold” by the nine ratings firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $14.00.

BCYC has been the subject of several research analyst reports. Morgan Stanley decreased their price objective on Bicycle Therapeutics from $13.00 to $12.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 8th. Citigroup restated a “market outperform” rating on shares of Bicycle Therapeutics in a report on Wednesday, June 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Wednesday, July 8th. Wall Street Zen upgraded shares of Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $12.00 price objective on shares of Bicycle Therapeutics in a research report on Thursday, April 30th.

Insider Buying and Selling

In related news, CEO Kevin Lee sold 5,905 shares of the company’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $4.27, for a total value of $25,214.35. Following the completion of the transaction, the chief executive officer directly owned 605,408 shares of the company’s stock, valued at approximately $2,585,092.16. This represents a 0.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 9,977 shares of company stock valued at $42,702. Insiders own 22.00% of the company’s stock.

Institutional Trading of Bicycle Therapeutics

A number of institutional investors have recently modified their holdings of BCYC. Man Group plc raised its position in Bicycle Therapeutics by 4.8% during the fourth quarter. Man Group plc now owns 42,860 shares of the company’s stock worth $303,000 after acquiring an additional 1,969 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Bicycle Therapeutics by 1.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 140,492 shares of the company’s stock valued at $976,000 after acquiring an additional 2,243 shares during the period. Flax Pond Capital LLC grew its position in shares of Bicycle Therapeutics by 1.4% in the 1st quarter. Flax Pond Capital LLC now owns 176,136 shares of the company’s stock valued at $817,000 after acquiring an additional 2,503 shares during the period. Ameriprise Financial Inc. increased its stake in shares of Bicycle Therapeutics by 21.7% during the 3rd quarter. Ameriprise Financial Inc. now owns 14,972 shares of the company’s stock worth $116,000 after purchasing an additional 2,668 shares during the last quarter. Finally, Clearstead Advisors LLC increased its stake in shares of Bicycle Therapeutics by 234.2% during the 4th quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock worth $33,000 after purchasing an additional 3,262 shares during the last quarter. 86.15% of the stock is currently owned by institutional investors.

Bicycle Therapeutics Trading Down 1.2%

BCYC stock opened at $4.16 on Tuesday. Bicycle Therapeutics has a 1-year low of $3.92 and a 1-year high of $9.18. The firm has a market cap of $290.41 million, a PE ratio of -1.32 and a beta of 1.55. The business’s 50-day moving average price is $4.28 and its two-hundred day moving average price is $5.09.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.25). The business had revenue of $0.89 million during the quarter, compared to the consensus estimate of $7.50 million. Bicycle Therapeutics had a negative return on equity of 35.74% and a negative net margin of 344.95%. On average, analysts forecast that Bicycle Therapeutics will post -1.97 earnings per share for the current year.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.